On the basis of these results, we suggested that an initial dose of irinotecan  ≤ 120 mg/m2 is possibly the optimal dose for the first cycle of FOLFIRINOX for Japanese advanced PC patients with UGT1A1-DV. The gene discussed is UGT1A1; the disease is pachyonychia congenita.